Humacyte, Inc.

Healthcare

NASDAQ:HUMA · NASDAQ Global Select

Market Cap $162.78M Beta 2.46 P/E (TTM) -1.9

$0.92 -3.35%

-$0.03 today

52W Low $0.55High $2.84

Vol 10.95M · Avg 8.14M

EPS (TTM) -$0.49Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-58.17%

Period High

$2.73

Period Low

$0.57

Latest

$0.92

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Achieve Life Sciences, Inc.

NASDAQ:ACHV

$506.11M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

$349.93M

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

$347.72M

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

$278.94M

Entrada Therapeutics, Inc.

NASDAQ:TRDA

$267.47M

Foghorn Therapeutics Inc.

NASDAQ:FHTX

$243.08M

Voyager Therapeutics, Inc.

NASDAQ:VYGR

$224.47M

Sagimet Biosciences Inc.

NASDAQ:SGMT

$216.62M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

$212.46M

Immuneering Corporation

NASDAQ:IMRX

$159.89M

What is the latest HUMA filing?

The latest filing shown is SC 13D/A dated Jun 15, 2026.

How many recent filings does HUMA have?

Intrinsic Alpha currently shows 20 recent filings for HUMA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.